You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 7,713,688

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,713,688

Title:	Methods and compositions for depleting specific cell populations from blood tissues
Abstract:	The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even rare cell types in high yield.
Inventor(s):	Collins; Daniel P. (Lino Lakes, MN)
Assignee:	BioE, LLC (St. Paul, MN)
Application Number:	11/627,762
Patent Claims:	1. A composition comprising: a) dextran; b) anti-glycophorin A antibody; c) two anti-CD9 antibodies of different isotypes; d) anti-CD 15 antibody; and e) a tandem antibody. 2. The composition of claim 1, wherein said tandem antibody comprises two different monoclonal antibodies. 3. The composition of claim 1, wherein said tandem antibody comprises any combination of IgM antibodies or IgG antibodies. 4. The composition of claim 1, wherein said tandem antibody comprises two anti-human antibodies. 5. The composition of claim 1, wherein the concentration of said tandem antibody is about 0.001 mg/L to about 15 mg/L. 6. The composition of claim 1, wherein said tandem antibody comprises a platelet-specific antibody other than an anti-CD9 antibody and an antibody directed against a cell surface antigen on a different cell type. 7. The composition of claim 6, wherein said platelet-specific antibody is an anti-CD 41 antibody. 8. The composition of claim 6, wherein said cell surface antigen is selected from the group consisting of CD2, CD3, CD4, CD8, CD10, CD13, CD14, CD16, CD19, CD20, CD23, CD31, CD33, CD34, CD38, CD44, CD45, CD56, CD66, CD72, CD83, CD90, CD94, CD161, and CD166. 9. The composition of claim 6, wherein said tandem antibody comprises an anti-CD 41 antibody and an anti-CD3 antibody. 10. The composition of claim 6, wherein said tandem antibody comprises an anti-CD 41 antibody and an anti-CD 19 antibody. 11. The composition of claim 6, wherein said tandem antibody comprises an anti-CD 41 antibody and an anti-CD8 antibody. 12. The composition of claim 1, further comprising phosphate buffered saline and/or heparin. 13. The composition of claim 1, further comprising divalent cations. 14. The composition of claim 13, wherein said divalent cations are Ca.sup.+2 or Mg.sup.+2. 15. The composition of claim 1, wherein the pH of said composition is between 6.8 to 7.8 or is between 7.2 to 7.4. 16. The composition of claim 1, wherein said anti-glycophorin A antibody is monoclonal. 17. The composition of claim 1, wherein said anti-glycophorin A antibody is an IgM antibody or an IgG antibody. 18. The composition of claim 1, wherein said anti-glycophorin A antibody is an anti-human glycophorin A antibody. 19. The composition of claim 1, wherein said anti-CD9 antibody is monoclonal. 20. The composition of claim 1, wherein said anti-CD9 antibodies are anti-human CD9 antibodies. 21. The composition of claim 1, wherein the different isotypes are IgG and IgM isotypes. 22. The composition of claim 1, wherein said anti-CD 15 antibody is monoclonal. 23. The composition of claim 1, wherein said anti-CD 15 antibody is an IgM antibody or an IgG antibody. 24. The composition of claim 1, wherein said anti-CD 15 antibody is an anti human CD15 antibody. 25. The composition of claim 1, wherein the concentration of said anti glycophorin A antibody, said anti-CD9 antibodies, or said anti-CD 15 antibody is about 0.001 mg/L to about 15 mg/L. 26. The composition of claim 1, said composition further comprising serum albumin. 27. The composition of claim 26, wherein said serum albumin is bovine serum albumin or human serum albumin. 28. The composition of claim 26, wherein the concentration of said serum albumin is about 0.5% to about 5%. 29. A composition comprising: a) dextran; b) heparin; c) divalent cations; d) anti-glycophorin A antibody; e) two anti-CD9 antibodies of different isotypes; f) anti-CD 15 antibody; and g) a tandem antibody. 30. The composition of claim 29, wherein said tandem antibody comprises an anti-CD 41 antibody and an anti-CD3 antibody. 31. The composition of claim 29, wherein said tandem antibody comprises an anti-CD 41 antibody and an anti-CD 19 antibody. 32. The composition of claim 29, wherein said tandem antibody comprises an anti-CD 41 antibody and an anti-CD8 antibody. 33. A kit comprising a blood collection vessel and the cell separation composition of claim 1. 34. The kit of claim 33, wherein said blood collection vessel is a blood bag or a vacuum tube. 35. The kit of claim 33, wherein said cell separation composition of claim 1 is housed within a sterile bag. 36. The kit of claim 35, wherein said sterile bag is operably connected to a sterile processing bag and said sterile processing bag is operably connected to a sterile storage bag. 37. The kit of claim 36, wherein said sterile storage bag comprises a cryopreservative. 38. A method for separating cells, said method comprising: a) contacting a blood cell-containing sample with a composition, said composition comprising: i. dextran; ii. anti-glycophorin A antibody; iii. anti-CD9 antibodies of two different isotypes; iv. anti-CD15 antibody; and v. a tandem antibody; b) allowing said sample to partition into an agglutinate and a supernatant phase; and c) recovering cells from said agglutinate or said supernatant phase. 39. The method of claim 38, wherein said sample is a human blood cell-containing sample. 40. The method of claim 38, wherein said sample is a peripheral blood sample, an umbilical cord sample, or a bone marrow sample. 41. The method of claim 38, wherein said cells are recovered from said supernatant phase. 42. The method of claim 38, wherein said cells are recovered from said agglutinate. 43. The method of claim 38, wherein said cells are recovered from both the agglutinate and supernatant phase. 44. The method of claim 38, wherein said sample is partitioned into said agglutinate and said supernatant phase at 1 .times.g.

Details for Patent 7,713,688

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978	⤷ Try a Trial	2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995	⤷ Try a Trial	2040-01-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.